Glucuronidation of piceatannol by human liver microsomes: Major role of UGT1A1, UGT1A8 and UGT1A10

Journal of Pharmacy and Pharmacology

Volumn 62, Issue 1, 2010, Pages 47-54

  Miksits, Michaela ^a   Maier Salamon, Alexandra ^a   Vo, Thanh Phuong Nha ^a   Sulyok, Michael ^b   Schuhmacher, Rainer ^b   Szekeres, Thomas ^c   Jäger, Walter ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF NATURAL RESOURCES AND LIFE SCIENCES   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Glucuronidation; Liver; Piceatannol; UGT

Indexed keywords

GLUCURONIDE; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A10; GLUCURONOSYLTRANSFERASE 1A8; ISOENZYME; PICEATANNOL; RECOMBINANT ENZYME;

ARTICLE; CATALYSIS; CONTROLLED STUDY; ENZYME INHIBITION; GLUCURONIDATION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; METABOLITE; MICHAELIS MENTEN KINETICS; PROTEIN FUNCTION; STRUCTURE ANALYSIS; TANDEM MASS SPECTROMETRY;

EID: 77949523329     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp.62.01.0004     Document Type: Article

References (35)

1. Bavaresco L. Role of viticultural factors on stilbene concentrations of grapes and wine. Drugs Exp Clin Res 2003; 29: 181-187.
2. Ku KL et al. Production of stilbenoids from the callus of Arachis hypogaea: a novel source of the anticancer compound piceatannol. J Agric Food Chem 2005; 53: 3877-3881.
3. Matsuda H et al. Effects of stilbene constituents from rhubarb on nitric oxide production in lipopolysaccharide-activated macrophages. Bioorg Med Chem Lett 2000; 10: 323-327.
4. Ferrigni NR et al. Use of potato disc and brine shrimp bioassays to detect activity and isolate piceatannol as the antileukemic principle from the seeds of Euphorbia lagascae. J Nat Prod 1984; 47: 347-352.
5. Piver B et al. Involvement of cytochrome P450 1A2 in the biotransformation of trans-resveratrol in human liver microsomes. Biochem Pharmacol 2004; 68: 773-782.
6. Potter GA et al. The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1. Br J Cancer 2002; 86: 774-778.
7. Murias M et al. Resveratrol analogues as selective cyclooxygenase-2 inhibitors: synthesis and structure-activity relationship. Bioorg Med Chem 2004; 12: 5571-5578.
8. Wieder T et al. Piceatannol, a hydroxylated analog of the chemopreventive agent resveratrol, is a potent inducer of apoptosis in the lymphoma cell line BJAB and in primary, leukemic lymphoblasts. Leukemia 2001; 15: 1735-1742.
9. Seow CJ et al. Piceatannol, a Syk-selective tyrosine kinase inhibitor, attenuated antigen challenge of guinea pig airways in vitro. Eur J Pharmacol 2002; 443: 189-196.
10. Murias M et al. Antioxidant, prooxidant and cytotoxic activity of hydroxylated resveratrol analogues: structure-activity relationship. Biochem Pharmacol 2005; 69: 903-912.
11. Ovesná Z et al. Antioxidant activity of resveratrol, piceatannol and 3,3′,4,4′,5,5′-hexahydroxy-trans-stilbene in three leukemia cell lines. Oncol Rep 2006; 16: 617-624.
12. Wolter F et al. Piceatannol, a natural analog of resveratrol, inhibits progression through the S phase of the cell cycle in colorectal cancer cell lines. J Nutr 2002; 132: 298-302.
13. Larrosa M et al. The grape and wine polyphenol piceatannol is a potent inducer of apoptosis in human SK-Mel-28 melanoma cells. Eur J Nutr 2004; 43: 275-284.
14. Kuo PL, Hsu YL. The grape and wine constituent piceatannol inhibits proliferation of human bladder cancer cells via blocking cell cycle progression and inducing Fas/membrane bound Fas ligand-mediated apoptotic pathway. Mol Nutr Food Res 2008; 52: 408-418.
15. Fritzer-Szekeres M et al. Biochemical effects of piceatannol in human HL-60 promyelocytic leukemia cells - synergism with Ara-C. Int J Oncol 2008; 33: 887-892.
16. Miksits M et al. In-vitro sulfation of piceatannol by human liver cytosol and recombinant sulfotransferases. J Pharm Pharmacol 2009; 61: 185-191.
17. Roupe K et al. Determination of piceatannol in rat serum and liver microsomes: pharmacokinetics and phase I and II biotransformation. Biomed Chromatogr 2004; 18: 486-491.
18. Walle T et al. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos 2004; 32: 1377-1382.
19. Wenzel E, Somoza V. Metabolism and bioavailability of transresveratrol. Mol Nutr Food Res 2005; 49: 472-481.
20. Maier-Salamon A et al. Increased transport of resveratrol across monolayers of the human intestinal Caco-2 cells is mediated by inhibition and saturation of metabolites. Pharm Res 2006; 23: 2107-2115.
21. Maier-Salamon A et al. Metabolism and disposition of resveratrol in the isolated perfused rat liver: role of Mrp2 in the biliary excretion of glucuronides. J Pharm Sci 2008; 97: 1615-1628.
22. King CD et al. UDP-glucuronosyltransferases. Curr Drug Metab 2000; 1: 143-161.
23. Aumont V et al. Regioselective and stereospecific glucuronidation of trans- and cis-resveratrol in human. Arch Biochem Biophys 2001; 393: 281-289.
24. Iwuchukwu OF, Nagar S. Resveratrol (trans-resveratrol, 3,5,4′-trihydroxy-trans-stilbene) glucuronidation exhibits atypical enzyme kinetics in various protein sources. Drug Metab Dispos 2008; 36: 322-330.
25. Soars MG et al. The effect of incubation conditions on the enzyme kinetics of udp-glucuronosyltransferases. Drug Metab Dispos 2003; 31: 762-767.
26. Hutzler JM, Tracy TS. Atypical kinetic profiles in drug metabolism reactions. Drug Metab Dispos 2002; 30: 355-362.
27. Wells PG et al. Glucuronidation and the UDP- glucuronosyltransferases in health and disease. Drug Metab Dispos 2004; 32: 281-290.
28. Romberg R et al. Pharmacokinetic-pharmacodynamic modeling of morphine-6-glucuronide-induced analgesia in healthy volunteers: absence of sex differences. Anesthesiology 2004; 100: 120-133.
29. Olson JA et al. Enhancement of biological activity by conjugation reactions. J Nutr 1992; 122: 615-624.
30. Scholz H, Schmitz W. Positive inotropic effects of digitoxin-and digoxin-glucuronide in human isolated ventricular heart muscle preparations. Basic Res Cardiol 1984; 79: 134-139.
31. Fromm MF et al. Influence of renal function on the steady-state pharmacokinetics of the antiarrhythmic propafenone and its phase I and phase II metabolites. Eur J Clin Pharmacol 1995; 48: 279-283.
32. Grubb NG et al. Stereoselective pharmacokinetics of ketoprofen and ketoprofen glucuronide in end-stage renal disease: evidence for a 'futile cycle' of elimination. Br J Clin Pharmacol 1999; 48: 494-500.
33. MacPhee IA et al. Pharmacokinetics of mycophenolate mofetil in patients with end-stage renal failure. Kidney Int 2000; 57: 1164-1168.
34. Sperker B et al. The role of beta-glucuronidase in drug disposition and drug targeting in humans. Clin Pharmacokinet 1997; 33: 18-31.
35. Pasqualini JR, Chetrite GS. Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer. J Steroid Biochem Mol Biol 2005; 93: 221-236.